These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Polymyxin B Induced Generalized Hyperpigmentation in Neonates. Gothwal S; Meena K; Sharma SD Indian J Pediatr; 2016 Feb; 83(2):179-80. PubMed ID: 26088547 [No Abstract] [Full Text] [Related]
5. Head and Neck Hyperpigmentation Probably Associated with Polymyxin B Therapy. Zavascki AP; Manfro RC; Maciel RA; Falci DR Ann Pharmacother; 2015 Oct; 49(10):1171-2. PubMed ID: 26187742 [No Abstract] [Full Text] [Related]
6. Polymyxin B-induced skin hyperpigmentation: a rare case report and literature review. Zheng G; Cao L; Che Z; Mao E; Chen E; He J BMC Pharmacol Toxicol; 2018 Jul; 19(1):41. PubMed ID: 29973293 [TBL] [Abstract][Full Text] [Related]
8. The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. Elias LS; Konzen D; Krebs JM; Zavascki AP J Antimicrob Chemother; 2010 Oct; 65(10):2231-7. PubMed ID: 20685752 [TBL] [Abstract][Full Text] [Related]
9. Skin testing after anaphylaxis to a topical Neosporin preparation. Schroer BC; Fox CC; Hauswirth DW Ann Allergy Asthma Immunol; 2008 Oct; 101(4):444. PubMed ID: 18939736 [No Abstract] [Full Text] [Related]
10. Higher incidence of neurotoxicity and skin hyperpigmentation in renal transplant patients treated with polymyxin B. Zhou Y; Li Y; Xie X; Song L; Lan G; Sun B; Tang T; Yan H; Zhang B; Xu P Br J Clin Pharmacol; 2022 Nov; 88(11):4742-4750. PubMed ID: 35508710 [TBL] [Abstract][Full Text] [Related]
12. Drug-associated canine pemphigus vulgaris? Who knows! Olivry T Vet Dermatol; 2007 Oct; 18(5):378-9; author reply 379. PubMed ID: 17845628 [No Abstract] [Full Text] [Related]
13. Polymyxin B versus other antimicrobials for the treatment of pseudomonas aeruginosa bacteraemia. Kvitko CH; Rigatto MH; Moro AL; Zavascki AP J Antimicrob Chemother; 2011 Jan; 66(1):175-9. PubMed ID: 20961911 [TBL] [Abstract][Full Text] [Related]
14. Incidence and predictors of acute kidney injury associated with intravenous polymyxin B therapy. Kubin CJ; Ellman TM; Phadke V; Haynes LJ; Calfee DP; Yin MT J Infect; 2012 Jul; 65(1):80-7. PubMed ID: 22326553 [TBL] [Abstract][Full Text] [Related]
17. Suspected polymyxin B-induced pemphigus vulgaris in a dog. Rybnícek J; Hill PB Vet Dermatol; 2007 Jun; 18(3):165-70. PubMed ID: 17470231 [TBL] [Abstract][Full Text] [Related]
18. Patterns of polymyxin B use in eight major cities of China in its first year of use. Yu Z; Yu L; Zhu J J Glob Antimicrob Resist; 2020 Mar; 20():342-343. PubMed ID: 32084604 [No Abstract] [Full Text] [Related]
19. Once-daily ofloxacin otic solution versus neomycin sulfate/polymyxin B sulfate/hydrocortisone otic suspension four times a day: a multicenter, randomized, evaluator-blinded trial to compare the efficacy, safety, and pain relief in pediatric patients with otitis externa. Schwartz RH Curr Med Res Opin; 2006 Sep; 22(9):1725-36. PubMed ID: 16968576 [TBL] [Abstract][Full Text] [Related]
20. Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center. Akajagbor DS; Wilson SL; Shere-Wolfe KD; Dakum P; Charurat ME; Gilliam BL Clin Infect Dis; 2013 Nov; 57(9):1300-3. PubMed ID: 23840000 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]